| Epigenetics: a landscape takes shape AD Goldberg, CD Allis, E Bernstein Cell 128 (4), 635-638, 2007 | 3251 | 2007 |
| Distinct factors control histone variant H3. 3 localization at specific genomic regions AD Goldberg, LA Banaszynski, KM Noh, PW Lewis, SJ Elsaesser, ... Cell 140 (5), 678-691, 2010 | 1369 | 2010 |
| Single-cell mutation analysis of clonal evolution in myeloid malignancies LA Miles, RL Bowman, TR Merlinsky, IS Csete, AT Ooi, ... Nature 587 (7834), 477-482, 2020 | 340 | 2020 |
| Hira-dependent histone H3. 3 deposition facilitates PRC2 recruitment at developmental loci in ES cells LA Banaszynski, D Wen, S Dewell, SJ Whitcomb, M Lin, N Diaz, ... Cell 155 (1), 107-120, 2013 | 296 | 2013 |
| Tumors metastatic to the heart AD Goldberg, R Blankstein, RF Padera Circulation 128 (16), 1790-1794, 2013 | 278 | 2013 |
| Distinct RNA motifs are important for coactivation of steroid hormone receptors by steroid receptor RNA activator (SRA) RB Lanz, B Razani, AD Goldberg, BW O'Malley Proceedings of the National Academy of Sciences 99 (25), 16081-16086, 2002 | 199 | 2002 |
| New functions for an old variant: no substitute for histone H3. 3 SJ Elsaesser, AD Goldberg, CD Allis Current opinion in genetics & development 20 (2), 110-117, 2010 | 189 | 2010 |
| Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub WA Wood, DS Neuberg, JC Thompson, MS Tallman, MA Sekeres, ... Blood advances 4 (23), 5966-5975, 2020 | 150 | 2020 |
| Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML M Stahl, K Menghrajani, A Derkach, A Chan, W Xiao, J Glass, AC King, ... Blood advances 5 (5), 1552-1564, 2021 | 119 | 2021 |
| Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure BJ Ball, CA Famulare, EM Stein, MS Tallman, A Derkach, M Roshal, ... Blood advances 4 (13), 2866-2870, 2020 | 106 | 2020 |
| Immune checkpoint inhibitors in acute myeloid leukemia: novel combinations and therapeutic targets M Stahl, AD Goldberg Current oncology reports 21, 1-10, 2019 | 99 | 2019 |
| Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts AM Zeidan, PC Boddu, MM Patnaik, JP Bewersdorf, M Stahl, RK Rampal, ... The Lancet Haematology 7 (8), e601-e612, 2020 | 76 | 2020 |
| BCMA-targeted CAR T-cell therapy plus radiotherapy for the treatment of refractory myeloma reveals potential synergy EL Smith, S Mailankody, M Staehr, X Wang, B Senechal, TJ Purdon, ... Cancer immunology research 7 (7), 1047-1053, 2019 | 65 | 2019 |
| Clinical insights for cervical ripening and labor induction using prostaglandins S Pierce, R Bakker, DA Myers, RK Edwards American Journal of Perinatology Reports 8 (04), e307-e314, 2018 | 65 | 2018 |
| Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia W Xiao, A Chan, MR Waarts, T Mishra, Y Liu, SF Cai, J Yao, Q Gao, ... Blood, The Journal of the American Society of Hematology 137 (10), 1377-1391, 2021 | 58 | 2021 |
| Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world CB Hirschfeld, LJ Shaw, MC Williams, R Lahey, TC Villines, S Dorbala, ... Cardiovascular Imaging 14 (9), 1787-1799, 2021 | 41 | 2021 |
| TP53 mutations predict poorer responses to CPX-351 in acute myeloid leukemia AD Goldberg, C Talati, P Desai, C Famulare, SM Devlin, N Farnoud, ... Blood 132, 1433, 2018 | 37 | 2018 |
| Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study G Garcia-Manero, AD Goldberg, ES Winer, JK Altman, AT Fathi, ... The Lancet Haematology 10 (4), e272-e283, 2023 | 29 | 2023 |
| Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: a phase I study AD Goldberg, E Atallah, D Rizzieri, RB Walter, KY Chung, A Spira, ... Leukemia Research 95, 106385, 2020 | 29 | 2020 |
| Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy CZ Brambilla, SM Lobaugh, JD Ruiz, PB Dahi, AD Goldberg, JW Young, ... Transplantation and cellular therapy 27 (9), 771. e1-771. e10, 2021 | 28 | 2021 |
Simon ElsässerKarolinska Institutet, SwedenE-mail confirmado em scilifelab.se
